Berger Financial Group Trims AbbVie Stake

Hedge fund reduces position in pharmaceutical giant by nearly 25% in Q4 2025

Apr. 19, 2026 at 7:42am

Got story updates? Submit your updates here. ›

An extreme close-up of highly detailed, metallic gears and machinery, representing the intricate financial infrastructure that supports a major pharmaceutical company's business.The complex financial machinery behind a leading pharmaceutical firm's operations.North Chicago Today

Berger Financial Group Inc., a financial services firm, reduced its stake in AbbVie Inc. (NYSE: ABBV) by 24.6% during the fourth quarter of 2025, according to a recent SEC filing. The firm now owns 15,097 shares of the pharmaceutical company's stock, valued at $3.45 million at the end of the quarter.

Why it matters

AbbVie is a major player in the pharmaceutical industry, with a diverse portfolio of drugs across several therapeutic areas. Tracking institutional investor activity in the stock can provide insights into market sentiment and potential future performance.

The details

Berger Financial Group sold 4,928 AbbVie shares during the fourth quarter, leaving the firm with a total of 15,097 shares. The sale represents a 24.6% reduction in Berger's position in the company. AbbVie's stock price has fluctuated in recent months, with shares trading between $168.54 and $244.81 over the past 52 weeks.

  • Berger Financial Group filed its 13F report for the fourth quarter of 2025 on April 19, 2026.
  • The firm reduced its AbbVie stake during the three-month period ending December 31, 2025.

The players

Berger Financial Group Inc.

A financial services firm that manages investments and provides financial advice to clients.

AbbVie Inc.

A global biopharmaceutical company that focuses on developing and commercializing specialty medicines across several therapeutic areas, including immunology, oncology, neuroscience, and women's health.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Berger Financial Group's AbbVie stake suggests the firm may have concerns about the company's near-term performance or valuation. However, AbbVie remains a major player in the pharmaceutical industry, and its stock continues to be widely held by institutional investors.